MIST - Milestone Pharmaceuticals Inc.
IEX Last Trade
2.12
0.020 0.943%
Share volume: 9,300
Last Updated: Fri 27 Dec 2024 08:29:55 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$2.10
0.02
0.95%
Fundamental analysis
25%
Profitability
25%
Dept financing
16%
Liquidity
75%
Performance
15%
Performance
5 Days
7.03%
1 Month
5.88%
3 Months
29.41%
6 Months
53.49%
1 Year
5.32%
2 Year
-43.91%
Key data
Stock price
$2.12
DAY RANGE
$1.95 - $2.14
52 WEEK RANGE
$1.34 - $2.40
52 WEEK CHANGE
$18.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Joseph G. Oliveto
Region: US
Website: milestonepharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: milestonepharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Milestone Pharmaceuticals Inc. focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada.
Recent news